Cellular changes leading to inhibition of programmed cell death (PCD) play an essential role in tumor development (90) . The elucidation of cell death pathways is thus an important area of study that may provide insights into the causes of drug resistance, thereby facilitating the development of novel anticancer therapies. In the last decade, the study of PCD has predominantly focused on apoptosis. However, PCD can be divided into at least three different categories: apoptosis, autophagy, and necrosis (21) . Apoptosis is characterized by cellular shrinkage, chromatin condensation, and DNA degradation, and is mediated by caspases (32) . Autophagy is characterized by the engulfment of cellular organelles, such as mitochondria and endoplasmic reticulum, by cytoplasmic vesicles. Necrosis has often been considered a passive process lacking any signaling event. However, necrosis could also occur in a controlled fashion (4, 6, 7, 9, 33, 47, 48, 59, 75, 89) . Thus, knowledge of the molecular mechanisms regulating necrosis could open the way to novel therapeutic approaches. On the one hand, analysis of the necrotic pathway may provide new options to destroy apoptosis-resistant tumor cells. On the other hand, a combination of therapies based on apoptosis mediators (e.g., caspases) and alternative therapies based on necrosis death effectors could offer a more effective approach.
Alkylating agents, like the nitrosourea N-methyl-NЈ-nitro-NЈ-nitrosoguanidine (MNNG), kill apoptotic-resistant cells (88) . They act by covalently modifying bases in the DNA, which results in massive production of DNA strand breaks and the induction of PCD. This type of death is controlled by the poly(ADP-ribose) polymerases (PARP), mainly represented by PARP-1 (113 kDa) and PARP-2 (63 kDa) (28, 85) . The activation of PARP results in poly(ADP-ribosyl)ation of key DNA repair proteins at the expense of NAD ϩ , which is cleaved into ADP-ribose and nicotinamide. When DNA damage is limited (e.g., by MNNG treatment at 0.5 to 10 M), this physiological machinery, which normally plays homeostatic protective and regulatory roles, could repair the injury (28, 63) . If DNA breaks are repaired, the damaged cells survive and the cellular NAD ϩ levels are restored by recycling nicotinamide with two ATP molecules. If DNA repair is not completely achieved, the cells undergo apoptosis by a caspase-dependent mechanism. When DNA damage is extensive (e.g., MNNG treatment at 100 to 500 M), cells cannot repair the injury. In this case, disproportionate activation of PARP depletes the cellular pools of NAD ϩ and ATP, driving the cell to a necrotic type of PCD (28, 63) . Therefore, nitrosoureas could induce apoptosis or necrosis, depending on the level of the DNA damage produced. In any case, these agents join a growing list of possible therapeutics that can kill cancer cells by inducing necrosis, such as cisplatin (56) or ␤-lapachone (51) .
Does necrosis induced by MNNG represent a programmed process? A strong link between PARP activation, release of the proapoptotic protein apoptosis-inducing factor (AIF) from mitochondria, and PCD associated with MNNG damage has been reported. In neuronal and cervical carcinoma cells, MNNG-induced death has been found to be PARP dependent but caspase independent (82, 85) . PARP chemical inhibitors, PARP-1 genetic ablation, or neutralizing anti-AIF antibodies inhibited MNNG-induced death (83, 85) . Moreover, in DNA damage-induced PCD, AIF is released from mitochondria by a mechanism implicating PAR polymers (84) , mitochondrial permeability transition (1) , reactive oxygen species production (35) , or RIP1/TRAF2-mediated Jun N-terminal protein kinase 1 activation (83) . Therefore, it seems that PARP controls alkylating DNA damage-induced necrosis through the release of AIF from mitochondria.
AIF is a bifunctional NADH oxidase involved in mitochondrial respiration and caspase-independent apoptosis (69, 74) . These two activities can be dissociated (8, 17, 18) . Indeed, AIF plays a prosurvival role through its redox activity in mitochondria, but a lethal role upon its translocation to the nucleus. Once in the nucleus, AIF causes partial chromatin condensation and DNA fragmentation (69) . This apoptogenic function of AIF is essential in some relevant experimental models of cell death (11-13, 23, 29, 35, 39, 40, 44, 49, 52, 55, 57, 77, 78, 85, 87) . To be released from mitochondria, AIF needs to be cleaved into tAIF by calpain or cathepsins (50, 54, 86) . Calpains are calcium-dependent proteases that are strongly implicated in PCD (53) . The two ubiquitously expressed forms of calpain, -and m-calpain, require the capn4-encoded regulatory subunit for activity, and capn4 knockout cells display resistance to endoplasmic reticulum-induced PCD (72) . The lysosomal cathepsins have also been implicated in apoptosis and necrosis upon the loss of lysosomal membrane integrity (89) .
Altogether, these findings emphasize the complexity of intracellular events triggering alkylating DNA damage-induced death. However, key questions remain to be addressed: How does the nuclear PARP activation trigger mitochondrial AIF release? Are calpains and/or cathepsins implicated in such release? Is the Bcl-2 family of proteins, which controls AIF release in apoptotic conditions (71) , also implicated in the release of AIF during necrosis? Does AIF knockdown inhibit necrosis? The aim of the present work was to examine these issues by using a panel of gene-knockout murine embryonic fibroblasts (MEFs). This approach has elucidated a novel p53-independent death pathway that sequentially involves PARP-1, calpains, Bax, and AIF.
MATERIALS AND METHODS
Cell culture and cell death induction and inhibition. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin (Invitrogen) and maintained at 37°C in a 5% CO 2 (10, 42, 72) . Wild-type (WT) cells from each lineage were used as controls. The genotypes of all cells were confirmed by immunoblotting.
To induce death, cells were treated with staurosporine (STS) (1 M; 12 h), H 2 O 2 (10 mM; 3 h), or MNNG (0.5 mM). For experiments with MNNG, the treatment medium was replaced after 15 min of incubation with fresh medium devoid of MNNG, and the cells (75 to 80% confluence) were cultured for the indicated times. Alternatively, cells were preincubated (1 h) with DHIQ (300 M; Calbiochem), oligomycin (6 M), Q-VD-OPh (QVD; 10 M), z-VADfmk, Boc-D-fmk (BAF), z-VDVAD-fmk, z-DEVD-fmk, z-VEID-fmk, z-IETDfmk, or z-LEHD-fmk (100 M; MP Biomedicals) before MNNG treatment. In a separate set of experiments, MEFs were cultured during the 48 h before MNNG treatment in DMEM without glucose (Invitrogen) supplemented with 10% fetal calf serum and 100 U/ml penicillin-streptomycin.
Flow cytometry and necrosis quantification. We used annexin V-fluorescein isothiocyanate (FITC) (0.1 g/ml) for the assessment of phosphatidylserine (PS) exposure, propidium iodide (PI; 0.5 g/ml) for cell viability analysis, and tetramethylrhodamine ethyl ester (TMRE; 20 nM) for the quantification of mitochondrial transmembrane potential (⌬⌿ m ). Cell death was recorded in a FACSCalibur cytofluorimeter (BD Biosciences). Lactate dehydrogenase (LDH) release was assessed with a CytoTox-ONE membrane integrity kit (Promega) in a Fluoroskan ascent fluorimeter (ThermoLab Systems).
DNA electrophoresis. Oligonucleosomal DNA fragmentation was detected by agarose gel electrophoresis as described elsewhere (58) .
Determination of ATP content. Cells treated as indicated were lysed, and the total ATP content was assessed with a luciferin-luciferase kit from Sigma. Luminescence was measured in a Berthold LB96V MicroLumat plus. The ATP content is expressed in arbitrary units relative to the number of cells analyzed. The ATP quantified in control cells is referred to as 100%.
tAIF recombinant protein. tAIF mouse recombinant protein was produced as described elsewhere (86) .
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay and cell-free system. The detection of 3Ј-OH DNA breaks was performed as described previously (87) . Alternatively, cells were costained with Hoechst 33342, examined in a Nikon Eclipse TE2000-U microscope, and analyzed using Nikon ACT-1 software.
A cell-free system was made as reported (69) . Briefly, MEF nuclei (10 3 nuclei/ l) were incubated in the presence of recombinant tAIF (5 g/ml) for 90 min at 37°C. Nuclei were used for TUNEL and Hoechst 33342 labeling and examined by fluorescence microscopy as described above. Alternatively, nuclei were stained with PI (0.5 g/ml) and analyzed by flow cytometry.
Protein extraction, cell fractionation, and immunoblotting. For whole protein extracts, 1 ϫ 10 6 cells were lysed in buffer containing 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 1% Triton X-100. For cytosolic purification, 2 ϫ 10 6 cells were resuspended in buffer containing 220 mM mannitol, 70 mM sucrose, 50 mM HEPES-KOH (pH 7.2), 10 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , and 0.025% digitonine, and kept on ice for 5 min. Lysed cells were centrifuged (16,000 ϫ g; 5 min; 4°C) and the supernatant was retained for the cytosolic fraction. The mitochondrial fractions were obtained by using a kit from Pierce and following the manufacturer's instructions. In vitro assays of AIF mitochondrial release upon atractyloside treatment were performed as described previously (86) . For PAR detection, 1 ϫ 10 6 cells were lysed as described previously (83) . Twenty micrograms of protein was loaded on 4 to 12% NuPAGE or linear sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred onto a nitrocellulose membrane. The membranes were probed with antibodies against Bax and caspase-9 (Upstate), Bcl-2 (BD Biosciences), PAR (clone LP98-10, Alexis), ICAD (inhibitor of caspase-activated DNase; Stressgen), ␣-spectrin (Chemicon), cleaved caspase-3 (BD Biosciences), Omi/HtrA2 (Alexis), Smac/ DIABLO (ProSci Inc.), AIF, actin, -calpain (domain IV), or cytochrome c. In some experiments, equal loading was confirmed by staining the membrane with naphthol blue.
Cell transfection and siRNA assays. For Bcl-2 overexpression assays, cells were stably transfected either with pcDNA3.1 empty vector (Neo) or pcDNA3.1-Bcl-2. Bcl-2 overexpression was confirmed by immunoblotting, and the levels of cell death induced by MNNG were determined by using flow cytometry with double labeling with annexin V and PI. For AIF downregulation assays, WT MEFs were transfected in a Nucleofector system (Amaxa) with two specific small interfering RNA (siRNA) double-stranded oligonucleotides designed against mouse AIF (AIF siRNA I, 5Ј-GCATGCTTCTATGATATAA-3Ј, and AIF siRNA II, 5Ј-CTGGCGGACTGGAAATAGA-3Ј). As a control, we used an siRNA against lamin A (control siRNA, 5Ј-CTGGACTTCCAGAAGAACA-3Ј). Seventy-two hours after the indicated siRNA transfection, PCD was induced by MNNG and the levels of cell death were determined by PI exclusion.
AIF and PAR immunofluorescence. Cells seeded on coverslips were fixed in methanol, incubated with an anti-AIF (raised against a peptide mapping at the C terminus of AIF [amino acids 593 to 613]; Sigma-Aldrich) (86) or an anti-PAR (clone 10H; Alexis) antibody (15) , and detected by anti-rabbit immunoglobulin G (IgG) conjugated with Alexa Fluor 488 (Invitrogen). Before being assessed, the cells were stained with Hoechst 33342 and mounted, and the green and blue fluorescence was observed in a confocal microscope (LSM-510 Meta; Zeiss). The cellular distribution of AIF was analyzed by using LSM-510 3.2 software. The quantification of chromatin condensation by fluorescence microscopy was per-formed in blind testing by at least two investigators, on 100 cells for each data point, and was repeated at least three times in independent experiments.
Bax activation, redistribution, and transfection. For flow cytometry or immunofluorescence analysis, cells were fixed in 1% paraformaldehyde, permeabilized with 0.1% saponin (10 min), incubated with an antibody designed against the active form of Bax (clone 6A7; BD Biosciences) (1 h), and detected by an anti-mouse IgG conjugated with Alexa Fluor 488 (Invitrogen). The cells were either analyzed by cytofluorometry or stained with Hoechst 33342 for immunuofluorescence assessment. Images were acquired with an Apotome-equipped Zeiss Axioplan (Axiocam MR; Zeiss) and examined with Axiovision software. For the assessment of Bax mitochondrial redistribution, cells were fixed as above, incubated with anti-Bax (Upstate) and anti-OxPhos complex IV subunit I (COX IV; Invitrogen) antibodies, and detected by anti-mouse and anti-rabbit IgG conjugated with Alexa Fluor (Invitrogen) according to standard procedures. Images were visualized in a Nikon Eclipse TE-2000-U fluorescent microscope, acquired with a Nikon digital DXM 1200 camera, and analyzed using Nikon ACT-1 software, version 2.2. For Bax immunoprecipitation, we used a method described elsewhere (27) . After the immunoprecipitation, samples were loaded on a 15% acrylamide gel and analyzed by immunoblotting for Bax as described above. For determining the levels of transient Bax overexpression, MEFs were transfected in a Nucleofector system (Amaxa) with pcDNA3-Bax or pcDNA3 empty vector. Twelve hours after the indicated transfections, PCD was induced by MNNG and cell viability assessed by PI labeling.
Caspase activity. Cells treated as indicated above were lysed in caspase assay buffer containing 40 mM HEPES-NaOH, pH 7.2, 300 mM NaCl, 20 mM dithiothreitol, 10 mM EDTA, 2% Nonidet P-40, 20% sucrose, and 100 M of N-acetyl-DEVD-AFC (7-amino-4-trifluoromethyl coumarin). The level of caspase activity was read in a fluorimeter.
Determination of total NAD ؉ content. The NAD ϩ concentrations were measured as described previously (88) in a Multiskan ascent spectrophotometer. The protein levels were determined by using a Bradford protein assay (Bio-Rad), and the NAD ϩ contents were related to the protein levels. Calpain activity. The calpain activities present in 30 g of total cell lysates were determined by cleavage of the fluorescent substrate N-succinyl-LLVY-AMC (Calbiochem) and expressed as the difference between calcium-dependent and calcium-independent fluorescence. Calcium-dependent fluorescence was measured after 30 min of incubation at 37°C in buffer containing 63 mM imidazole-HCl, pH 7.3, 10 mM ␤-mercaptoethanol, and 5 mM CaCl 2 . Calciumindependent fluorescence was measured under the same conditions but using buffer without CaCl 2 and containing 1 mM EDTA and 10 mM EGTA. The fluorescence was recorded in a Fluoroskan ascent fluorimeter. The levels of calpain activity in live cells were detected by using the cell-permeable calpain substrate Boc-Leu-Met-CMAC (Invitrogen). Cells spread on coverslides were incubated for 30 min with 50 M of calpain substrate in Dulbecco's modified Eagle's medium. The cells were then treated for 1 h with 0.5 mM of MNNG, observed in a Nikon Eclipse TE2000-U microscope, and analyzed using Nikon ACT-1 software, version 2.2.
Unless specified, reagents were from Sigma-Aldrich.
RESULTS
The DNA alkylating agent MNNG induces caspase-independent necrosis. To identify the type of cell death induced by alkylating DNA damage, we first examined the biochemical events induced by MNNG treatment in MEFs. As depicted in Fig. 1A , MNNG-induced death is a time-dependent process, with significant alterations observed as soon as 6 h after treatment and a maximum effect at 12 h. By measuring the level of LDH release, which only occurs in necrotic conditions, we determined that the cytotoxic process induced by MNNG is similar to necrosis (Fig. 1B) . MNNG-treated cells underwent PS exposure, loss of cell viability, and ⌬⌿ m dissipation ( Fig. 1A and C). In contrast, MNNG treatment was not coupled to oligonucleosomal DNA degradation (Fig. 1E) or signs of lysosomal permeabilization (data not shown). The cellular alterations observed after MNNG treatment are associated with a rapid drop in ATP levels ( Fig. 1D ) and mitochondrial release of tAIF (the cleaved form of AIF) (86) , cytochrome c, Omi/ HtrA2, or Smac/DIABLO to the cytosol ( Fig. 1F and G) . These results confirm that, as in apoptotic PCD (45) VOL. 27, 2007 PARP-1, CALPAINS, Bax, AND AIF REGULATE NECROSIS 4847 metabolic status (Fig. 1D , right histogram). As an internal control, we verified that cells cultured in the absence of glucose and treated with oligomycin are unable to generate ATP (data not shown). Importantly, in MEFs, MNNG treatment induces necrosis only in cells using the glycolytic pathway (Fig. 1D ). We further explored the involvement of caspases in MNNGmediated necrosis. First, we assessed the activation of two key players of caspase-dependent PCD: caspase-9 and caspase-3. These proteases are synthesized as inactive proenzymes of 49 and 32 kDa, respectively. After a caspase-dependent apoptotic insult, such as treatment with STS, caspase-9 and -3 are cleaved to yield the active p37/39 and p17 subunits of 37, 39, and 17 kDa, respectively. Immunoblot analysis demonstrated that, in contrast to the results from treatment with STS, caspase-9 and caspase-3 did not become activated even 12 h after MNNG treatment (Fig. 1H ). This result demonstrated that MNNGinduced necrosis does not involve the activation of caspase-9 or caspase-3. Furthermore, in contrast to the results of STS treatment, caspase-3-dependent ICAD cleavage was not observed in MNNG-treated cells (Fig. 1H ). Additional evidence that MNNG does not induce caspase-3 activity was seen in the results of a fluorogenic substrate-based assay (Fig. 1I) . Finally, MNNG treatment of caspase-9 and caspase-3 knockout MEFs resulted in levels of cell death (Fig. 1J ) and tAIF release from mitochondria ( Fig. 1K ) similar to those seen in WT cells. Together, these results show that MNNG-induced PCD is independent of caspase-9 and caspase-3.
On a broader scale, the caspase independence of the death process induced by MNNG was explored using a large panel of caspase inhibitors. We found that MNNG-induced PCD was not affected by the pancaspase inhibitors QVD, z-VAD, and BAF or by inhibitors of caspase-2, -3, -6, -7, -8, -9, or -10 ( Fig.  1L) .
Our data confirm that the caspase-independent PCD induced by MNNG treatment is similar to necrosis. The biochemical alterations observed after MNNG treatment linked PS exposure, loss of cell viability, ⌬⌿ m disruption, and ATP drop with the release of the cleaved form of AIF from mitochondria to the cytosol.
AIF redistributes from mitochondria to nucleus and controls MNNG-induced necrosis. During caspase-independent PCD, AIF translocates from mitochondria to the nucleus, where it causes a type of nuclear alteration, named stage I, characterized by rippled nuclear contours and partial chromatin condensation (68) . Thus, we tested whether MNNG-induced AIF relocation provokes this nuclear hallmark in MEFs. In untreated cells, AIF was excluded from the nucleus and displayed a punctate mitochondrial localization pattern ( Fig.  2A) . However, after MNNG treatment, a portion of AIF was found within the nucleus, as determined by confocal and computerized image analysis ( Fig. 2A) . Kinetic studies established a correlation between necrosis (Fig. 1A, B , and C), mitochondrial translocation of tAIF (Fig. 1D) , and the advancement of nuclear PCD (Fig. 2B) . Interestingly, TUNEL assessment revealed that stage I of the chromatin condensation was accompanied by 3Ј-OH DNA breaks in MNNG-induced necrosis (Fig. 2C) . We thus generated the mouse tAIF recombinant protein to investigate whether the 3Ј-OH DNA breaks observed in MNNG-treated MEFs could be directly caused by tAIF. This recombinant protein was added to highly purified MEF nuclei in a cell-free in vitro system, and the levels of nuclear 3Ј-OH DNA breaks were assessed by two independent methods: cytofluorometry, to quantify the nuclei presenting DNA breaks, and immunofluorescence, to visualize the levels of TUNEL positivity. In both systems, we observed that, in vitro, recombinant tAIF causes the same nuclear apoptogenic effects as those observed in MNNG-treated cells ( Fig. 2C and  2E ). Finally, using siRNA-mediated knockdown of AIF, we confirmed that a reduction of AIF expression prevented MNNG-induced PCD (Fig. 2F) . These results demonstrated that MNNG treatment induced necrosis through a direct effect of tAIF on the nucleus.
MNNG-induced AIF release and necrosis is a PARP-1-dependent and PARP-2/p53-independent process. We next investigated the mechanisms controlling AIF release in this type of cell death. The PARP family of proteins, mainly represented by PARP-1 and PARP-2, are regulators of the necrosis pathway and, depending on the cell death inducer, can promote AIF mitochondrial release in a p53-dependent or p53-independent manner (16, 36) . Here we observed that, as in WT cells, MNNG triggered necrosis in PARP-2 (Fig. 3A) . Therefore, MNNG-induced PCD was selectively regulated by PARP-1. It is important to note that, in the absence of PARP-1 expression, only a residual PAR activity was detected early after DNA damagemediated cell death (Fig. 3B) MEFs correlates with the negative TUNEL labeling (Fig. 3E) , the lack of generation of stage I of chromatin condensation (Fig. 3F) , and the absence of tAIF release from mitochondria (Fig. 3G) . These data indicated that MNNG induced tAIF release and necrosis in a PARP-1-dependent and a PARP-2/ p53-independent manner. Calpains regulate AIF release and MNNG-mediated necrosis. We next focused on the characterization of the molecular pathway regulating the PARP-1-dependent mitochondrial AIF release. AIF needs to be processed by calpains or cathepsin B, L, or S in the intermembrane space of mitochondria to yield a proapoptotic protein which is released to the cytosol (86) . We therefore tested whether these proteases were implicated in MNNG-induced AIF release and necrosis. To address this issue, we used a panel of knockout MEFs for cathepsin B (Cath or Cath L Ϫ/Ϫ MEFs, both mitochondrial AIF release and MNNG-induced necrosis remained unaffected ( Fig. 4A and  B) . In contrast, MNNG-induced AIF release and necrosis were completely abolished in Capn4 Ϫ/Ϫ MEFs ( Fig. 4C and D) . Moreover, as expected from the absence of tAIF in extramitochondrial compartments in MNNG-treated Capn4
MEFs, the results of TUNEL labeling were also negative (Fig.  4E) . As an internal control for calpain activation in MNNGtreated cells, we used a cell-permeable fluorescent calpain substrate, which reports calpain activity in live cells. This approach showed that MNNG treatment induced rapid calpain activation in WT, but not in Capn4 Ϫ/Ϫ , MEFs (Fig. 4F) . These results were further corroborated by the results of a fluorescence assay (Fig. 4G) and immunoblotting (Fig. 4H) . Hence, calpains were activated early after MNNG treatment, and the ensuing AIF release and cell death correlated with the levels of calpains but not of cathepsins.
Calpains act downstream of PARP-1 in MNNG-induced death. To gain insights into the molecular ordering of PARP-1 and calpains in MNNG-induced necrosis, we first tested whether PARP-1 was activated in Capn4 Ϫ/Ϫ MEFs. As indicated above, activation of PARP-1 results in poly(ADP-ribosyl)ation at the expense of NAD ϩ . Thus, PARP-1 activation is detected biochemically by the inverse relationship existing between the cellular levels of PAR and NAD ϩ . As shown by the formation of PAR polymers, PARP-1 was equally activated in WT and Capn4 Ϫ/Ϫ MEFs (Fig. 5A) , demonstrating that PARP-1 is activated even in the absence of calpains. In agreement with this, MNNG treatment caused a rapid decrease in NAD ϩ cellular levels in both WT and Capn4 Ϫ/Ϫ MEFs. The specificity of the PARP-dependent NAD ϩ loss associated with MNNG treatment was confirmed by using a pharmacological PARP inhibitor, DHIQ (Fig. 5B) . Together, these data showed that PARP-1 activation was calpain-independent during MNNG-induced death, suggesting that calpain activity is placed downstream from PARP-1 activation in this process.
To confirm this hypothesis, we used a biochemical approach to determine whether calpains were activated in PARP-1 Ϫ/Ϫ cells after MNNG treatment. First, we immunodetected the cleaved forms of the calpain substrate spectrin. Spectrin is a 240-kDa protein cleaved by calpains and caspase-3 in cell death conditions. While both calpains and caspase-3 produce fragments of 150 kDa, these proteases also produce distinct breakdown products: a 147-kDa fragment specifically generated by calpains and a 120-kDa fragment generated by caspase-3 (30) . As depicted in Fig. 5C , WT MEFs treated with MNNG showed the 150-kDa common breakdown product and the 147-kDa calpain-specific product but not the 120-kDa caspase-3-specific product. However, spectrin was not cleaved in MNNG-treated PARP-1 Ϫ/Ϫ MEFs, indicating that calpains were inactive in the absence of PARP-1. As a positive control for caspase-3-mediated spectrin cleavage, we demonstrated that WT and PARP-1 Ϫ/Ϫ cells treated with the caspase-dependent apoptosis inductor STS displayed the 120-kDa spectrin breakdown product (Fig. 5C) . As a control for calpain-mediated spectrin cleavage, we corroborated that this protein was not cleaved in Capn4 Ϫ/Ϫ MEFs after alkylating DNA damage treatment (Fig. 5C) . Finally, the blockade of calpain activation in MNNG-treated PARP-1 Ϫ/Ϫ MEFs was confirmed by using a fluorescent substrate (Fig. 5D) . Together, these results revealed that PARP-1 controls calpain activation during alkylating DNA damage-induced necrosis. Bax, but not Bak, is necessary for MNNG-induced AIF release and necrosis. Next, we analyzed how the mitochondrial outer membrane became permeable to AIF after MNNG treatment. For this purpose, we studied the involvement of the Bcl-2 family of proteins in this process. Mitochondrial outer membrane permeabilization (MOMP) arises from a pore formed by proapoptotic Bcl-2 family members such as Bax and Bak, either alone or in combination with other proteins, like ANT (adenine nucleotide translocase) or VDAC (voltage-dependent anion channel) (37) . Thus, we assessed whether Bak or Bax regulates MNNG-mediated AIF release and PCD. Bak Ϫ/Ϫ and WT MEFs displayed comparable MNNG-induced cell death responses. However, Bax Ϫ/Ϫ MEFs were largely resistant to MNNG treatment ( Fig. 6A and B) . In contrast, WT, Bak Ϫ/Ϫ , and Bax Ϫ/Ϫ cells treated with the caspase-dependent apoptosis inducer STS displayed similar cell death levels (Fig. 6B, right histogram) , confirming that the single genetic ablation of Bax or Bak does not confer resistance to apoptotic PCD. Therefore, it seems that, in contrast to classical apoptosis, specific ablation of Bax in programmed necrosis is sufficient to preclude cell death. In MNNG-induced necrosis, Bax, but not Bak, deficiency disabled tAIF release from mitochondria to the cytosol (Fig. 6C) . Consequently, MNNG-treated Bax Ϫ/Ϫ cells were TUNEL negative and did not present signs of nuclear chromatin condensation ( Fig. 6D and E) . Finally, to confirm that AIF release and necrosis were due to the specific lack of Bax, we reintroduced Bax into the Bax Ϫ/Ϫ cells by transient transfection. As depicted in Fig. 6F , Bax transfection resensitized Bax Ϫ/Ϫ cells to MNNG-induced AIF release and necrosis. Together, our results identify Bax as a key component of the alkylating DNA damage-induced necrotic pathway.
Molecular ordering of PARP-1, calpains, and Bax in MNNG-induced necrosis. Further, we sought to determine the molecular ordering of PARP-1, calpains, and Bax activation in MNNG-induced necrosis. We first assessed the relationship between PARP-1 and Bax. As shown in Fig. 7A , we detected the PAR polymers in Bax Ϫ/Ϫ cells, as well as in WT MEFs. Consequently, cellular NAD ϩ depletion occurred similarly in both types of cells. This indicated that PARP-1 is activated independently of Bax during MNNG-induced necrosis. Taking these results together with our earlier results (Fig. 5) , we have therefore demonstrated that PARP-1 is activated upstream of both calpains and Bax during MNNG-induced death.
The relative sequence of calpains and Bax activation was next assessed by measuring calpain activity in MNNG-treated WT and Bax Ϫ/Ϫ cells and by assessing the levels of Bax activation in MNNG-treated WT and Capn4 Ϫ/Ϫ MEFs. As depicted in Fig. 7B , calpains were activated similarly in WT and Bax Ϫ/Ϫ MEFs, meaning that Bax is dispensable for the calpain activation process. In contrast, we showed a time-dependent increase of activated Bax in WT, but not in Capn4 Ϫ/Ϫ , MNNGtreated cells (Fig. 7C) . This was further substantiated by the use of immunoprecipitation and immunofluorescence approaches, which detected activated Bax in MNNG-treated WT but not Capn4 Ϫ/Ϫ cells ( Fig. 7D and E) . The results obtained by using these three independent methods indicated that Bax activation depends on calpains. Bax is thus activated downstream of calpains in MNNG-induced cell death.
MNNG induces Bax translocation from cytosol to mitochondria. To investigate the impact of Bax activation in MNNGinduced necrosis, we analyzed its subcellular redistribution. Immunofluorescence detection revealed a diffuse pattern of Bax distribution in untreated cells, which is compatible with the cytosolic localization of the soluble inactive protein (20, 76, 80) (Fig. 8A) . Upon the induction of necrosis with MNNG, the diffuse pattern of fluorescence is replaced by a granular/punctate pattern that colocalizes with mitochondrial protein Cox IV (Fig. 8A) , indicating that Bax relocalizes from the cytosol to mitochondria after MNNG treatment. This interpretation was fully confirmed by subcellular fractionation. Mitochondria and cytosol from WT MEFs induced to undergo cell death in response to MNNG or STS were purified. As shown in Fig. 8B , Bax is localized in the cytosol of untreated cells. However, upon stimulation with MNNG or STS, a significant fraction of Bax redistributes to mitochondria. Indeed, the Bax redeployment correlated strictly with the above-described Bax activation (Fig. 7) and the necrotic response of MEFs to MNNG treatment ( Fig. 1 and 8A) . In this sense, Bax mitochondrial redistribution was not observed in PARP-1 Ϫ/Ϫ and Capn4
MNNG-resistant cells (Fig. 8A, right panels) .
Overall, our data demonstrate that MNNG treatment induces a PARP-1/calpain-dependent conformational change of Bax, which provokes its activation and translocation to mitochondria. The presence of Bax in mitochondria results in mitochondrial perturbation, as evidenced by the loss of ⌬⌿ m .
Bcl-2 regulates MNNG-induced necrosis. The importance of the Bcl-2 family of proteins in the control of alkylating DNA damage-mediated necrosis was further assessed in cells overexpressing Bcl-2. Indeed, it has been reported that Bcl-2 prevents Bax-dependent PCD by blocking dimerization of the protein in mitochondria (3, 14, 26, 38, 41, 43, 73, 76) . Moreover, Bcl-2 controls mitochondrial AIF release in apoptotic conditions (50, (69) (70) (71) and Bcl-2 is also able to inhibit certain forms of necrotic cell death (34, (65) (66) (67) , suggesting that apoptosis and necrosis share common Bax/Bcl-2 steps. As shown in the kinetic analysis included in Fig. 8C , after MNNG treatment, the viability of Bcl-2-overexpressing cells was superior to that of WT (Neo-transfected) cells. Importantly, Bcl-2 overexpression disabled tAIF release from mitochondria to the cytosol after MNNG treatment (Fig. 8D) . Consequently, MNNG-treated Bcl-2-overexpressing cells were TUNEL negative and did not present signs of nuclear chromatin condensation (data not shown). Finally, to confirm that the inhibiting effect of Bcl-2 in MNNG-induced necrosis was due to the specific action of the protein on mitochondria (e.g., abolishing tAIF mitochondrial release), we demonstrated that, even if PARP-1 and calpains remained activated (Fig. 8E) , mitochondrial function (e.g., ⌬⌿ m ) was maintained in Bcl-2-overexpressing cells after MNNG treatment (Fig. 8C ). Taking these results together with our above-described results, we revealed that Bcl-2 and Bax present opposing effects in regulating mitochondrial features characterizing MNNG-induced necrosis. Collectively, the results presented here establish a novel molecular mechanism for alkylating DNA damage-induced cell death, a Bcl-2-controlled necrotic process. MMNG induces PARP-1 activity, which leads to calpain activation, which in turn regulates Bax activation and the conversion of AIF to tAIF. Active Bax is required for MOMP and AIF release. Upon transfer into the nucleus, tAIF causes 3Ј-OH DNA breaks and necrosis (Fig. 9) .
DISCUSSION
Nitrosoureas are a developed group of alkylating DNAdamaging agents, which are best represented by MNNG. These agents are active anticancer drugs (61) . It is well established that PARP-dependent translocation of the mitochondrial protein AIF to the nucleus is required in MNNG-induced necrosis. However, the molecular mechanism triggered by MNNG to induce AIF release and necrosis is unknown. In this report, we provide novel insights into this molecular mechanism, which includes the sequential activation of PARP-1, calpains, Bax, and AIF in a single cell death pathway. Our data, obtained in a large panel of MEF cells, demonstrate that MNNG-mediated necrosis proceeds via the induction of cellular alterations that are independent of some of the major apoptotic effectors, such as the caspases. Nevertheless, MNNG-induced necrotic PCD shares common features with the apoptotic form of cell death. Certain biochemical features are conserved, namely, outer leaflet exposure of PS in the plasma membrane or alterations to mitochondria (e.g., ⌬⌿ loss or tAIF release). In addition, as for apoptosis, necrosis associated with alkylating DNA damage is dependent on the input from different cellular compartments. First, the nucleus, through PARP-1 activation; second, the cytosol, through calpain and Bax activities; and finally, mitochondria, through the Bcl-2-controlled tAIF release.
Traditionally, death associated with MNNG was attributable to the fact that PARP-1 activation correlated with a rapid cellular depletion of NAD ϩ and ATP. Two major ATP generation mechanisms involving NAD ϩ exist in a cell: (i) glycolysis, which uses cytosolic NAD ϩ as a substrate, and (ii) mitochondrial oxidative phosphorylation, which uses mitochondrial NAD ϩ . Cytosolic and mitochondrial NAD ϩ are not exchanged. In interleukin-3 (IL-3)-dependent hematopoietic cells, IL-3 deprivation, glucose withdrawal, or glycolytic blockade renders MNNG inefficient (88) . Moreover, IL-3 deprivation, which blocks cellular glycolysis and the generation of the NAD ϩ cytosolic pool, preserves ATP levels after MNNG treatment. This suggests that the glycolytic control of the metabolic state of the cell regulates DNA damage-mediated death (46, 88, 89) . Our results with MEFs fully confirm these data. We first demonstrated that glucose deprivation or oxidative phosphorylation inhibition does not preclude cellular ATP generation. MEFs use glycolysis or mitochondrial oxidative phosphorylation to support their energetic needs. However, only MEFs using glycolysis are sensitized for alkylating DNA damage-induced necrosis; cells using oxidative phosphorylation (e.g., MEFs cultured in the absence of glucose) are significantly protected from MNNG treatment. Therefore, it seems that PARP-1 uses the glycolytic/cytosolic pool of NAD ϩ to control MNNG-induced necrosis.
New studies confirm the hypothesis that energy collapse is not the sole mechanism by which PARP contributes to cell death. A "death link" between PARP, mitochondria, and AIF has been clearly established (16) . More recently, a report established that PAR polymers produced by PARP-1 play an essential role in AIF-mediated necrosis (84) . Our current results confirm the p53-independent role of PARP-1 (and not PARP-2) in the release of tAIF from mitochondria. Thus, it seems that the level (or the nature) of PAR polymers produced by PARP-1 is essential in MNNG-induced cell death. Polymers synthesized by the other members of the PARP family, such as PARP-2, were unable to activate the AIF-mediated necrotic pathway. Our data strongly favor the hypothesis that the complexity and concentration of each structural type of PAR may vary depending on the PARP implicated (31) . Given the complexity of PAR structures and the existence of distinct PARP enzymes, this heterogeneity seems to reflect the different signaling functions of PARP family members and the specificities of PAR signaling pathways. Most importantly, we demonstrate that tAIF release depends on PARP-1-mediated calpain and Bax activation. Further analysis is therefore necessary to unravel the nature of the PAR polymers produced by PARP-1 and the relationships between these polymers and calpain and Bax activation. In any case, the specificity of the PARP-1 activation and the control of the AIF mitochondrial redistribution mediated by the calpain cysteine proteases and the proapoptotic member of the Bcl-2 family of proteins, Bax, are essential to an understanding of the interplay between the multiple MNNG-induced signals. The old concept of PARP-1 as a passive killer instigated by DNA damage could be replaced by its emerging role as an active key participant in a novel, molecularly orchestrated form of PCD. Bcl-2 proteins are the main regulators of the mitochondrial death pathway. They can either suppress or promote mitochondrial changes by regulating the release of key proteins from mitochondria. Thus, the Bcl-2 family determines the cellular susceptibility to PCD (14) . How Bcl-2 family proteins control the release of mitochondrial proteins is still unclear. However, it is clear that multidomain proapoptotic proteins such as Bax and Bak participate in this release (37, 41) . Bax activation or Bak conformational changes lead to the formation of a mitochondrial pore that facilitates the release of mitochondrial proapoptotic proteins. Therefore, in apoptotic PCD, the combined genetic ablation of both Bax and Bak confer resistance to apoptosis (79) . Strikingly, we find that, in alkylating DNA damage-induced necrosis, the single genetic inactivation of Bax precludes AIF release and necrosis. Thus, in this form of PCD, Bax is necessary, but Bak is dispensable. Despite the structural similarities and the genetically demonstrated redundancy in apoptosis of Bax and Bak (62) , these data support the hypothesis that Bax and Bak do not perform redundant functions in all cell death models (5, 19) . We also prove that, like apoptosis, necrosis could be a Bcl-2-controlled process. The mechanisms by which Bcl-2 inhibits apoptosis are only partially elucidated. Most experimental data suggest that Bcl-2 has to act on mitochondrial membranes to prevent apoptosis (14, 22, 25, 26, 38, 41, 64, 73, 76) . On the one hand, Bcl-2 prevents the apoptosis-associated release of proapoptotic proteins from the mitochondrial intermembrane space via the outer mitochondrial membrane. In addition to this effect on the outer mitochondrial membrane, Bcl-2 prevents the disruption of the inner ⌬⌿ m during apoptosis. Our data reveal that, in programmed necrosis, Bcl-2 prevents cell death in a similar way: (i) by maintaining the subcellular compartmentalization of AIF and (ii) by stabilizing the ⌬⌿ m . These findings demonstrate a previously unknown role of Bcl-2 in the regulation of necrotic PCD, in addition to the well-known role of this protein in apoptotic PCD.
In light of our results, calpain appears to link PARP-1 activity to Bax activation and AIF release during MNNG-induced necrosis. Recently, Bax has been identified as a target of calpains, suggesting that the generation of the 18-kDa Bax fragment by calpains is an early event in the induction of apoptosis via calpains, Bax, and mitochondria (2, 24, 81) . However, p21 Bax is not cleaved into p18 Bax in MNNG-mediated PCD (R. S. Moubarak, V. J. Yuste, and S. A. Susin, unpublished observation). Thus, calpains control Bax activation via a yet-unknown mechanism in alkylating DNA damage-mediated necrosis. Concerning the cleavage of AIF into tAIF, three previous reports have shown that AIF is a membrane-integrated mitochondrial protein that becomes a soluble and proapoptotic protein after its cleavage by calpain and/or cathepsins (50, 54, 86) . Remarkably, the present results indicate that calpain, and not cathepsins, controls mitochondrial AIF release during MNNG-induced death. As PARP-1-dependent MNNG-induced death does not promote lysosomal membrane permeabilization, cathepsins would therefore be excluded from this cell death pathway.
Little is known about the upstream mechanisms which regulate tAIF release from mitochondria. Our data suggest that this process requires the cooperative upstream action of calpains and Bax. On the one hand, calpains cleave AIF, yielding tAIF. On the other hand, Bax facilitates the MOMP that is necessary for AIF release. Consequently, even if calpains were activated in Bax Ϫ/Ϫ cells (Fig. 7) , AIF would not be released from mitochondria to the cytosol. Thus, in characterizing calpains and Bax as the main elements in alkylating DNA damage-induced necrosis, we also provide the first insights into the molecular pathway governing tAIF release from mitochondria.
During apoptotic PCD, a number of distinct DNA condensation and fragmentation events take place. Two different degrees of chromatin condensation have been defined, partial chromatin condensation (stage I) and condensation into pyknotic apoptotic bodies (stage II) (60, 68) . In necrotic PCD, our results demonstrated that MNNG-treated MEFs displayed stage I of chromatin condensation. The level of this nuclear modification correlated with the level of TUNEL-positive DNA fragmentation. Importantly, we showed that these two nuclear alterations were caused by AIF. Indeed, by knockdown of AIF, we demonstrated that the action of nuclear-translo- cated AIF was crucial in alkylating DNA damage-induced necrosis. This is an important issue that sheds new light on the role of AIF in PCD.
Controversies still exist regarding which model of PCD is important in cell regulation. Partial resolution of these controversies may come with the recognition that apoptosis and necrosis frequently represent alternate outcomes of a similar pathway, particularly for cell death mediated by Bcl-2 proteins (e.g., Bax/Bcl-2) or proapoptotic mitochondrial proteins (e.g., AIF). This report confirms that, similar to apoptosis, necrosis could be a regulated form of PCD. This necrotic program can occur in cells possessing an intact mechanism of apoptotic cell destruction (e.g., STS-mediated apoptosis). This implies the existence of a necrotic signaling pathway that could be modulated independently from the classical apoptotic pathway. Of note, many tumors carry alterations inactivating the apoptosis pathway (e.g., p53 mutations). Based on our current results, it seems conceivable that this alternative necrotic pathway might be activated to induce cell death in these tumor cells (e.g., by using Bax-derived peptides to provoke AIF mitochondrial release). In this sense, our results might pave the way for the development of novel pharmacological tools to circumvent the commonly observed chemotherapy resistance of transformed cells. In addition, DNA damage-induced necrosis occurs selectively in growing cells, not in vegetative cells (88, 89) . Indeed, cells grown to confluence were less sensitive to alkylating DNA damage-mediated death than subconfluent cells. Because uncontrolled and invasive growth defines a key characteristic of FIG. 9 . Schematic model for MNNG-induced cell death. MNNG-induced DNA damage leads through PARP-1 to calpain activation. Calpain in turn activates Bax, resulting in its translocation from the cytosol to mitochondria, where it facilitates the release of tAIF from the mitochondrial intermembrane space to the cytosol. The activated calpain also regulates AIF release by cleaving the membrane-anchored AIF to the soluble form tAIF. Once liberated in the cytosol, tAIF translocates to the nucleus, where it generates 3Ј-OH DNA breaks and stage I of chromatin condensation. (89) , are sensitized to MNNGinduced death. Thus, our study on PARP-1, calpains, Bax, and AIF provides a new angle of analysis for the development of novel tumor cell-specific therapeutic agents. Overall, this report provides substantial progress in the understanding of (i) the molecular events regulating alkylating DNA damage-induced cell death, (ii) the molecular mechanisms which control mitochondrial release of AIF, and (iii) a novel signaling pathway which distinguishes necrosis from apoptotic PCD.
